Inhibiting transcription in cancers with aberrant KRAS expression has proven to be detrimental to tumor cells, revealing their dependency on KRAS independent of its mutational status and provides a wide scope for therapeutic intervention [12,13,14,15]. This evidence concerns the gene KRAS and cancer.